Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors
Teva Pharmaceutical reported Q3 2025 adjusted EPS of $0.78 on $4.48 billion revenue, beating estimates and sending shares up 10–11% to a new 52-week high. The company raised 2025 guidance, citing strong sales of Austedo and other branded drugs, and Fitch upgraded its credit rating in May. Debt fell to $16.79 billion. Teva’s forward P/E remains below industry averages despite the stock’s sharp recovery.